PLUR earnings analysis
What we found in PLUR's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Pluri Inc.'s Q3 2026 10-Q report highlights continued revenue challenges with a significant year-over-year decline in revenue. While cost-cutting measures are in place, increased research and development costs have maintained high net losses for the company, leading to ongoing liquidity concerns.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Decline
- Q3 2026 revenue fell to $167,000, down 61% from $427,000 in Q3 2025.
- Increasing R&D Costs
- R&D expenses surged by 30% year-over-year in Q3 2026, totaling $3,962,000 compared to $3,043,000 in Q3 2025.
- Cash Position Deteriorating
- Cash and cash equivalents decreased to $9,548,000 as of March 31, 2026, down from $26,680,000 in March 2025.
- Significant Net Loss
- Net loss for Q3 2026 was $6,172,000, slightly down from $6,335,000 in Q3 2025, reflecting high operational costs.
- Working Capital Deficit
- As of March 31, 2026, the working capital deficit was $21,543,000, indicating severe liquidity challenges.
- Positive Financial Income
- Other financial income improved to $889,000 in Q3 2026 from $714,000 in Q3 2025, reflecting hedging income.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Severe Liquidity Concerns
- The company has a working capital deficit of $21,543,000, with cash resources expected to last less than three months.
- Ongoing High Net Losses
- Accumulated deficit rose to $460,996,000, showcasing unsustainable operational loss levels.
- Revenue Generation Challenges
- Management projects no significant revenue generation in the next twelve months, raising doubts about business viability.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.55
What they said about what is next.
Outlook remains bleak; management does not anticipate significant revenue nor improvement in operational outcomes.
The filing reads worse than the one before it.
What came before.
- 10-Q · February 12, 2026
- Pluri reported quarterly revenue of $198,000 and GAAP diluted EPS of -$0.71 for the three months ended December 31, 2025. Revenue was up modestly year-over-year (+$13,000, +7.0%) but down versus the prior quarter…
- 10-Q · February 11, 2025
- Pluri reported three-month revenue of $185,000 for the period ended December 31, 2024 (up from $105,000 in the prior-year quarter) and a narrower net loss of $3,110,000 (net loss per share $0.53 vs $0.96 prior-year).…
- 10-Q · November 12, 2024
- Pluri reported revenues of $326,000 for the three months ended September 30, 2024, up from $54,000 a year earlier, driven by CDMO services and an agtech POC. Despite the revenue lift, the company recorded a net loss of…
- 10-K · September 18, 2024
- Pluri Inc. (PLUR) positions itself as a multi-vertical cell‑expansion platform (regenerative medicine, immunotherapy, CDMO, food tech and agtech) with recent commercial and partnership traction but remains early-stage…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing PLUR makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever